Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab + NK cells in HER2+ Gastric Cancer
NCT02805829Phase 2Unknown
- Sponsor
- Xuzhou Medical University
- Start
- Jan 2017
- Primary completion
- Jan 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of troculeucel in gastric cancer (GC), sponsored by Xuzhou Medical University. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 2 years. Status: unknown.
02
Drugs
troculeucel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02805829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805829.